Liangwei Wang Selected Research

Interferon Type I

1/2021	Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
1/2020	Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
1/2018	Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
1/2017	Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liangwei Wang Research Topics

Disease

7	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021 - 04/2013
2	Herpes Zoster 01/2017 - 11/2016
2	Infections 11/2016 - 04/2013
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2023
1	Rheumatoid Arthritis 01/2023
1	Necrosis 01/2023
1	Substance-Related Disorders (Drug Abuse) 05/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Glioma (Gliomas) 09/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2019
1	Neutropenia 01/2018
1	Lymphopenia (Lymphocytopenia) 01/2018
1	Arthritis (Polyarthritis) 01/2018
1	Exanthema (Rash) 01/2018
1	Human Influenza (Influenza) 01/2017
1	Asthma (Bronchial Asthma) 01/2017

Drug/Important Bio-Agent (IBA)

6	Monoclonal AntibodiesIBA 01/2020 - 04/2013
4	Interferon Type IIBA 01/2021 - 01/2017
4	InterferonsIBA 01/2020 - 04/2013
4	anifrolumabIBA 01/2020 - 01/2017
3	sifalimumabIBA 01/2020 - 04/2013
2	CD40 Ligand (CD40L)IBA 01/2023 - 01/2019
2	Alprostadil (Muse)FDA LinkGeneric 01/2021 - 01/2018
1	InflammasomesIBA 01/2023
1	AntibodiesIBA 01/2023
1	Antirheumatic Agents (DMARD)IBA 01/2023
1	Methotrexate (Mexate)FDA LinkGeneric 01/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	Rheumatoid FactorIBA 01/2023
1	Methamphetamine (Desoxyn)FDA LinkGeneric 05/2022
1	Long Noncoding RNAIBA 09/2020
1	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 01/2020
1	Thymic Stromal LymphopoietinIBA 01/2017
1	GlucocorticoidsIBA 01/2017
1	tezepelumabIBA 01/2017
1	CytokinesIBA 01/2017